Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Agenus Inc (AGEN)

Agenus Inc (AGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Agenus (AGEN) Q2 Earnings Miss Estimates, Revenues Beat

Agenus (AGEN) reports wider-than-expected loss and beats sales estimates in the second quarter of 2019.

AGEN : 2.84 (+0.35%)
GILD : 64.11 (+1.54%)
ACOR : 2.93 (+8.52%)
GSK : 40.37 (+0.45%)
Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates

Agenus (AGEN) delivered earnings and revenue surprises of -15.15% and 192.92%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

AGEN : 2.84 (+0.35%)
Agenus: 2Q Earnings Snapshot

LEXINGTON, Mass. (AP) _ Agenus Inc. (AGEN) on Thursday reported a loss of $51.9 million in its second quarter.

AGEN : 2.84 (+0.35%)
Agenus Reports Second Quarter 2019 Financial Results and Provides Corporate Update

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1, and cancer vaccines provided corporate updates and reported financial...

AGEN : 2.84 (+0.35%)
Agenus Milestone Triggers $7.5M Payment

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1 and cancer vaccines, announced today that the FDA has accepted the...

AGEN : 2.84 (+0.35%)
Agenus to Report Second Quarter 2019 Financial Results on August 8, 2019 and Host Conference Call and Webcast

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its second quarter 2019 financial results before the market opens...

AGEN : 2.84 (+0.35%)
Agenus Appoints Don Vidic as Vice President and Head of Commercial

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline of novel clinical and preclinical stage checkpoint antibodies, cell therapies and neoantigen vaccines, today announced the appointment...

AGEN : 2.84 (+0.35%)
Agenus (AGEN) Upgraded to Buy: What Does It Mean for the Stock?

Agenus (AGEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AGEN : 2.84 (+0.35%)
Gilead Inks Deal With Carna Biosciences for Immuno-Oncology

Gilead (GILD) teams up with Carna Biosciences to develop and commercialize small molecule compounds in immuno-oncology.

AGEN : 2.84 (+0.35%)
NVO : 51.22 (-0.85%)
GILD : 64.11 (+1.54%)
GSK : 40.37 (+0.45%)
Why Is Agenus (AGEN) Down 6.3% Since Last Earnings Report?

Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AGEN : 2.84 (+0.35%)
MiMedx Announces Comprehensive Board Refreshment Plan in Cooperation with Prescience Point

MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or the "Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that the Company's board of directors...

AGEN : 2.84 (+0.35%)
MDXG : 5.5000 (+9.34%)
PTCI : 0.5500 (+37.50%)
Agenus' (AGEN) Pipeline Progression on Track Amid Competition

Agenus (AGEN) is developing its pipeline candidates and has an array of collaboration contracts to its credit that bodes well for growth.

ANIK : 57.47 (+2.24%)
AGEN : 2.84 (+0.35%)
GILD : 64.11 (+1.54%)
AGTC : 3.18 (+3.25%)
Agenus (AGEN) Q1 Earnings Beat Estimates, Revenues Miss

Agenus' (AGEN) earnings beat estimates in the first quarter of 2019. Sales marginally miss the same.

AGEN : 2.84 (+0.35%)
GNMSF : 203.3500 (+0.69%)
GILD : 64.11 (+1.54%)
FCSC : 1.88 (+3.30%)
Agenus (AGEN) Surpasses Q1 Earnings Estimates

Agenus (AGEN) delivered earnings and revenue surprises of 140.00% and -4.65%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

AGEN : 2.84 (+0.35%)
Agenus: 1Q Earnings Snapshot

LEXINGTON, Mass. (AP) _ Agenus Inc. (AGEN) on Thursday reported first-quarter net income of $17.4 million, after reporting a loss in the same period a year earlier.

AGEN : 2.84 (+0.35%)
Agenus Reports First Quarter 2019 Financial Results and Provides Corporate Update

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, provided corporate updates and reported financial...

AGEN : 2.84 (+0.35%)
Agenus, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 9, 2019 / Agenus, Inc. (NASDAQ: ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 9, 2019 at 8:30 AM Eastern Time.

AGEN : 2.84 (+0.35%)
Agenus to Report First Quarter 2019 Financial Results on May 9, 2019 and Host Conference Call and Webcast

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, will release its first quarter 2019 financial...

AGEN : 2.84 (+0.35%)
Why Is Agenus (AGEN) Down 13% Since Last Earnings Report?

Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AGEN : 2.84 (+0.35%)
Biotechs Strive to Provide Patients With More Affordable Treatment Options

The American Cancer Society estimated that in 1991, cancer deaths peaked at 215 deaths per 100,000 persons. As of 2014, the rate dropped significantly to just 161 deaths per 100,000 persons, representing...

AGEN : 2.84 (+0.35%)
OMED : 0.93 (+4.49%)
ATOS : 2.11 (-3.21%)
SNETD : 0.3900 (+14.71%)
SNET : 0.0103 (+63.49%)
SNSS : 0.85 (+1.81%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
AIZ -0.74 , WELL +0.63 , SBAC +0.55 , CCI +1.94 , SO +0.46
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar